Somewhat Favorable News Coverage Somewhat Unlikely to Impact Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price
Media coverage about Alnylam Pharmaceuticals (NASDAQ:ALNY) has trended somewhat positive on Friday, according to Accern. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Alnylam Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.5787526735402 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s scoring:
- There Are Mixed Technical Signals in Alnylam Pharmaceuticals, Inc. (ALNY) – StockNewsGazette (stocknewsgazette.com)
- EARNINGS SUMMARY: Details of Alnylam Pharmaceuticals Inc. Q2 Earnings Report (rttnews.com)
- ALNY Beats EPS Loss Estimates By $0.10. Misses On Revenues. (investorsbuz.com)
- Alnylam Pharmaceuticals, Inc. : Investor Network: Alnylam Pharmaceuticals, Inc to Host Earnings Call (4-traders.com)
- Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs (fool.com)
Alnylam Pharmaceuticals (NASDAQ ALNY) traded up 3.00% during mid-day trading on Friday, reaching $78.22. The company’s stock had a trading volume of 847,539 shares. The company has a 50-day moving average price of $80.94 and a 200-day moving average price of $61.92. The firm’s market cap is $6.89 billion. Alnylam Pharmaceuticals has a 12-month low of $31.38 and a 12-month high of $86.92.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by $0.12. The company had revenue of $15.93 million for the quarter, compared to analysts’ expectations of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 48.01%. Alnylam Pharmaceuticals’s quarterly revenue was up 82.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.05) earnings per share. On average, equities research analysts expect that Alnylam Pharmaceuticals will post ($5.23) earnings per share for the current year.
A number of research analysts have recently weighed in on the company. Morgan Stanley restated an “equal weight” rating on shares of Alnylam Pharmaceuticals in a report on Monday, July 10th. Stifel Nicolaus restated a “buy” rating and issued a $56.00 target price (up previously from $47.00) on shares of Alnylam Pharmaceuticals in a report on Thursday. Chardan Capital reaffirmed a “buy” rating and set a $124.00 price target (down from $131.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday. BMO Capital Markets began coverage on Alnylam Pharmaceuticals in a research report on Monday, April 17th. They set an “outperform” rating and a $73.00 price target for the company. Finally, Ladenburg Thalmann Financial Services set a $80.00 price target on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 17th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and an average price target of $81.74.
WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/08/11/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-alnylam-pharmaceuticals-nasdaqalny-stock-price.html.
In other news, VP Michael Mason sold 9,375 shares of the company’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $70.00, for a total value of $656,250.00. Following the completion of the sale, the vice president now directly owns 5,625 shares in the company, valued at approximately $393,750. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Akshay Vaishnaw sold 43,750 shares of the company’s stock in a transaction on Monday, May 15th. The stock was sold at an average price of $65.00, for a total value of $2,843,750.00. Following the completion of the sale, the senior vice president now owns 43,047 shares of the company’s stock, valued at $2,798,055. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 64,125 shares of company stock valued at $4,325,000. Company insiders own 4.30% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.